Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | THRB | P10828 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1103812 | 0.87 | SMN1; SMN2 (1.00) | MAPTALOX15SMN1; SMN2TSHRHPGD | |
| SCHEMBL19627186 | 0.87 | THRB (0.61) | MAPTALOX15SMN1; SMN2THRBTSHR | |
| SCHEMBL17793564 | 0.84 | THRB (0.59) | MAPTALOX15SMN1; SMN2THRBTSHR | |
| SCHEMBL3611257 | 0.83 | THRB (0.61) | MAPTALOX15SMN1; SMN2THRBTSHR | |
| SCHEMBL24938760 | 0.82 | ALOX15 (0.59) | MAPTALOX15SMN1; SMN2THRBTSHR | |
| SCHEMBL19627154 | 0.82 | MAPT (0.60) | MAPTALOX15SMN1; SMN2THRBTSHR | |
| SCHEMBL11582560 | 0.81 | ALDH1A1 (0.55) | MAPTALOX15SMN1; SMN2THRBTSHR | |
| SCHEMBL7533220 | 0.81 | ALOX15 (0.58) | MAPTALOX15SMN1; SMN2TSHRHPGD | |
| SCHEMBL6614852 | 0.81 | ALOX15 (0.58) | MAPTALOX15SMN1; SMN2THRBTSHR | |
| SCHEMBL3046007 | 0.81 | ALOX15 (0.58) | MAPTALOX15SMN1; SMN2THRBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | MEDSHINE DISCOVERY INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| WO-2021119249-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| US-20200223837-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2020-07-16 | — | — | US | disclosed |
| EP-3638664-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | European Molecular Biology Laboratory (DE) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018229193-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2018-12-20 | — | — | WO | disclosed |
| US-8742132-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| US-8742132-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| US-8742132-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| EP-2094689-B1 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| EP-2094689-B1 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| US-8193236-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193236-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-18 | — | — | US | disclosed |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-18 | — | — | US | disclosed |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-18 | — | — | US | disclosed |
| EP-2094689-A2 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074752-A2 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074752-A2 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| US-20020128272-A1 | 4,5,6, and 7-indole and indoline derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-09-12 | — | — | US | disclosed |
| US-6391882-B1 | PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | H. LUNDBECK A/S (DK) | 2002-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | PSMA6, PSMC1, PSMA1 | MAPT 1812/4885ALOX15 4024/4885SMN1; SMN2 723/4885 |
| US-20020128272-A1 | 4,5,6, and 7-indole and indoline derivatives, their preparation and use | HTR2C, HTR1A, HTR7 | MAPT 2061/4885ALOX15 2590/4885SMN1; SMN2 3596/4885 |
| US-20200223837-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | SUCNR1, CBR1, CYP2A13 | MAPT 2012/4885ALOX15 126/4885SMN1; SMN2 1329/4885 |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | IDH3A, IDH2, INMT | MAPT 3141/4885ALOX15 4144/4885SMN1; SMN2 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.